Clinical Cancer Research · 2007 · 71 citations · 21 references
MedicineOncologyRadiation OncologyCarcinogenesisMolecular OncologyOncogenesBreast Cancer RadiobiologyBreast Cancer RadiotherapyBreast PathologyHer2-positive Breast CancerMalignant NeoplasmsRadiation CarcinogenesisBreast Cancer Molecular SubtypesEstrogen Receptor ExpressionHer2 AmplificationHer2 ExpressionHer2 Gene AmplificationMalignant Breast TumorsRadiation EffectsRadiation-associated Breast Cancer
PURPOSE: Neither hormone-related nor genetics risk factors have been associated with the development of highly proliferative HER2-positive breast carcinomas. Because the majority of HER2-positive tumors present the amplification of the oncogene, we asked whether genomic instability triggered by irradiation might be involved in the induction of HER2-overexpressing breast carcinomas. EXPERIMENTAL DESIGN: Sixty-six infiltrating breast carcinomas from patients treated with radiation therapy for Hodgkin's lymphoma or other pediatric solid tumors and a control series of 61 consecutive sporadic breast tumors were analyzed by immunohistochemistry for HER2 expression with HercepTest. A panel of antibodies against estrogen receptor, progesterone receptor, c-kit, cytokeratin 5/6, p53, and ki67 antigen was also used to identify differentiation subsets and molecular characteristics of the analyzed breast carcinomas. RESULTS: Although no differences between the two tumor series were found with respect to HER2 expression scored 2+ and 3+, the percentage of 3+ HER2-positive tumors was significantly higher in patients irradiated during breast maturation compared with patients irradiated after breast maturation (35.3% versus 12.5%, P = 0.046). In the latter group, 52.5% of the breast carcinomas showed basal-like differentiation (estrogen receptor, progesterone receptor, and HER2 negative) versus only 5.9% in the group irradiated during breast development (P < 0.0001). Analysis adjusted for age confirmed the significant increase in basal-like tumor development in patients irradiated within 4 years of menarche, but also showed that the differences between patients irradiated before and after puberty in HER2 3+ tumor frequencies are due to age-related differences in HER2 3+ tumor onset. CONCLUSION: Together, our data indicate that the development of HER2-positive tumors correlates with timing rather than type of carcinogenic hits and provide clear evidence that radiation is a risk factor for breast carcinomas showing basal-like differentiation.
21
Molecular portraits of human breast tumours
Charles M. Perou, Thérese Sørlie, Michael B. Eisen et al. · Nature · 2000 · 16.3K citations
Risk of Second Cancers after Treatment for Hodgkin's Disease
M A Tucker, C. Norman Coleman, R S Cox et al. · New England Journal of Medicine · 1988 · 726 citations
Stem cells in normal breast development and breast cancer
MS Wicha, Gabriela Dontu, Muhammad Al‐Hajj et al. · Breast Cancer Research · 2003 · 541 citations · Full text
Medicine, Cancer Biology, Oncology +15